SOLENO THERAPEUT. DL-001 (6XC) - Total Liabilities
Based on the latest financial reports, SOLENO THERAPEUT. DL-001 (6XC) has total liabilities worth €113.72 Million EUR (≈ $132.94 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of SOLENO THERAPEUT. DL-001 to assess how effectively this company generates cash.
SOLENO THERAPEUT. DL-001 - Total Liabilities Trend (2021–2025)
This chart illustrates how SOLENO THERAPEUT. DL-001's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of SOLENO THERAPEUT. DL-001 to evaluate the company's liquid asset resilience ratio.
SOLENO THERAPEUT. DL-001 Competitors by Total Liabilities
The table below lists competitors of SOLENO THERAPEUT. DL-001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pandox AB (publ)
ST:PNDX-B
|
Sweden | Skr78.83 Billion |
|
Enerflex Ltd.
TO:EFX
|
Canada | CA$2.37 Billion |
|
TAV HAVALIMAN.HLDG ADR/4
F:5THA
|
Germany | €3.31 Billion |
|
Wenzhou Yihua Connector Co Ltd
SHE:002897
|
China | CN¥4.27 Billion |
|
Ningxia Jiaze Renewables Corp
SHG:601619
|
China | CN¥14.81 Billion |
|
Jeju Semiconductor Corp
KQ:080220
|
Korea | ₩95.37 Billion |
|
Shenzhen Overseas Chinese Town Co Ltd
SHE:000069
|
China | CN¥216.86 Billion |
|
Energisa S.A
SA:ENGI3
|
Brazil | R$62.29 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SOLENO THERAPEUT. DL-001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is SOLENO THERAPEUT. DL-001 worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SOLENO THERAPEUT. DL-001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SOLENO THERAPEUT. DL-001 (2021–2025)
The table below shows the annual total liabilities of SOLENO THERAPEUT. DL-001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €113.72 Million ≈ $132.94 Million |
+32.44% |
| 2024-12-31 | €85.86 Million ≈ $100.38 Million |
+270.34% |
| 2023-12-31 | €23.18 Million ≈ $27.10 Million |
+43.56% |
| 2022-12-31 | €16.15 Million ≈ $18.88 Million |
-9.07% |
| 2021-12-31 | €17.76 Million ≈ $20.76 Million |
-- |
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more